SynthesisOncotarget2016

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.

Wei Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.